Pneumococcal

CDC researchers investigate pneumococcal disease cases and intervention strategies within a North Carolina correctional facility from June 14 to July 30, 2024.

Researchers investigate PCV25 developments and potential use of the vaccine among adults who are healthy and naïve to the pneumococcal vaccine.

Pneumococcal aortitis is a rare but life-threatening aortic infection that highlights the concerning interplay between pneumococcal disease and cardiovascular disease risk and mortality.

Researchers explore the serotypes, vaccination, and risk factors associated with pneumococcal disease mortality among in-hospital patients in Spain.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

The top pneumococcal stories of 2025 explored the evolving landscape of pneumococcal vaccination.

With little evidence on vaccine coverage for people living with HIV, researchers explored pneumococcal vaccine rates between 2014 and 2023.

With constant vaccine and guideline updates reserved for pneumococcal diseases, pharmacists continue to be the authority on pneumococcal vaccine administration.

In part 3 of our interview with Megan Smith, PharmD, she discusses the common reasons for hesitancy among patients, specifically for the pneumococcal vaccine.

Megan Smith, PharmD, discusses how pharmacists have taken reigns in boosting pneumococcal vaccine rates across health care.

Megan Smith, PharmD, breaks down the public health sector’s current understanding and approach toward pneumococcal vaccines.

Exploring the real-time capabilities of chatbots and artificial intelligence (AI), researchers investigate how this technology would impact older adults’ pneumococcal vaccine rates.

Researchers explore community-acquired pneumococcal-related hospital admissions among adults from 2000 to 2019 and assess pneumococcal immunization’s impact after the year 2015.

Researchers investigate serotype distribution and antimicrobial resistance among children in Mexico with pneumococcal meningitis.

Researchers conduct a cost-effectiveness analysis to uncover the public health and economic impacts of PCV20 among Australian children.

After nearly 20 years of pneumococcal conjugate vaccine use in the Portuguese vaccine schedule, researchers explore serotype distribution in bacteria causing adult invasive pneumococcal disease (IPD).

With disease cases increasing substantially between 2012 and 2024, higher-valent vaccines are necessary to protect against nonvaccine serotypes and invasive pneumococcal disease.

Steve Leonard, PharmD, BCIDP, joins Drug Topics on World Pneumonia Day to discuss pharmacists’ role in managing the disease.

Study findings highlight the need for further exploration into the racial and ethnic trends of pneumococcal vaccination rates.

To celebrate World Pneumonia Day, Steve Leonard, PharmD, BCIDP, joined us to discuss the variety of pneumonia types and the treatment options commonly prescribed.

To optimize vaccine strategies among young people with Down syndrome, researchers explore the prevalence of adequate immune responses following pneumococcal vaccination.

Pneumococcal conjugate vaccines significantly reduce pneumonia incidence in children, but safety concerns warrant further investigation in future studies.

PCV21 improved all outcomes for individuals aged 19 to 64 years, including invasive pneumococcal disease, postmeningitis sequelae, and nonbacteremic pneumococcal pneumonia.

At the NCPA 2025 Annual Convention & Expo, Jeannie Grubbs, PharmD, manager at Publix Pharmacy, presented on the reasons why pneumococcal vaccine development is an ongoing process.

Researchers investigate which pneumococcal strains were most responsible for invasive infections among children in Poland.